Curis (CRIS) Net Margin (2010 - 2025)
Curis' (CRIS) quarterly Net Margin came in at 1700.88% in Q4 2025, up 200357.0% YoY from N/an in Q4 2024, and up 798.92% on a QoQ basis from 243.36% in Q3 2025.
Curis (CRIS) Net Margin (2010 - 2025) Analysis & Trends
Curis (CRIS) has 16 years of Net Margin data on file, last reported at 1700.88% in Q4 2025.
- Quarterly Net Margin rose 200357.0% year-over-year to 1700.88% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 123.29% (up 26587.0% YoY) and the FY2025 annual result came in at 2300.22%, up 3644.0% from the prior year.
- Net Margin climbed to 1700.88% in Q4 2025, from 243.36% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1700.88% in Q4 2025 to a low of 803.65% in Q1 2022.
- A 5-year average of 356.93% and a median of 450.45% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin slumped 35645 bps — and 2025, when it jumped 200357 bps.
- Tracing CRIS's Net Margin over 5 years: stood at 439.52% in 2021, then increased by 18 bps to 359.61% in 2022, then retreated by 17 bps to 421.96% in 2023, then advanced by 28 bps to 302.69% in 2024, then jumped by 662 bps to 1700.88% in 2025.
- The last three Net Margin figures came in at 1700.88% (Q4 2025), 243.36% (Q3 2025), and 312.59% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | Curis | 3.46 Mn | -2.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,700.88% |
| Sep 30, 2025 | -243.36% |
| Jun 30, 2025 | -312.59% |
| Mar 31, 2025 | -446.05% |
| Dec 31, 2024 | -302.69% |
| Sep 30, 2024 | -363.08% |
| Jun 30, 2024 | -479.62% |
| Mar 31, 2024 | -611.70% |
| Dec 31, 2023 | -421.96% |
| Sep 30, 2023 | -454.85% |
| Jun 30, 2023 | -581.84% |
| Mar 31, 2023 | -526.47% |
| Dec 31, 2022 | -359.61% |
| Sep 30, 2022 | -470.58% |
| Jun 30, 2022 | -677.23% |
| Mar 31, 2022 | -803.65% |
| Dec 31, 2021 | -439.52% |
| Sep 30, 2021 | -365.42% |
| Jun 30, 2021 | -515.31% |
| Mar 31, 2021 | -463.86% |